Sorriso Pharmaceuticals Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 5

Sorriso Pharmaceuticals General Information

Description

Developer of disease-modifying antibodies designed for the treatment of inflammatory diseases, including Crohn's disease and ulcerative colitis. The company develops potent antibodies that can be delivered orally, providing clinical impacts similar to those of injectable antibody therapeutics, enabling healthcare providers to relieve the treatment burden for patients who rely on drugs that can only be administered via injections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9295 South 1300 East
  • Suite 3
  • Sandy, UT 84094
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 9295 South 1300 East
  • Suite 3
  • Sandy, UT 84094
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sorriso Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-May-2024 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 22-Dec-2021 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view Sorriso Pharmaceuticals’s complete valuation and funding history, request access »

Sorriso Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Sorriso Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Sorriso Pharmaceuticals Patents

Sorriso Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026178289-A1 Il-23 and tnf-alpha inhibitors for use in autoimmune and inflammatory disorders Pending 21-Feb-2025
WO-2025076251-A1 Dosages of il-23 and tnf-alpha inhibitors for use in autoimmune and inflammatory disorders Inactive 05-Oct-2023
EP-4750804-A1 Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders Pending 26-Jul-2023
US-20260209332-A1 Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders Pending 26-Jul-2023
WO-2025024723-A1 Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders Inactive 26-Jul-2023 C07K16/241
To view Sorriso Pharmaceuticals’s complete patent history, request access »

Sorriso Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sorriso Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biovision Ventures Venture Capital Minority
Lundbeckfonden BioCapital Venture Capital Minority
New Enterprise Associates Venture Capital Minority
Pappas Capital Venture Capital Minority
Magnify Accelerator/Incubator
To view Sorriso Pharmaceuticals’s complete investors history, request access »

Sorriso Pharmaceuticals FAQs

  • When was Sorriso Pharmaceuticals founded?

    Sorriso Pharmaceuticals was founded in 2020.

  • Where is Sorriso Pharmaceuticals headquartered?

    Sorriso Pharmaceuticals is headquartered in Sandy, UT.

  • What is the size of Sorriso Pharmaceuticals?

    Sorriso Pharmaceuticals has 8 total employees.

  • What industry is Sorriso Pharmaceuticals in?

    Sorriso Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Sorriso Pharmaceuticals a private or public company?

    Sorriso Pharmaceuticals is a Private company.

  • What is Sorriso Pharmaceuticals’s current revenue?

    The current revenue for Sorriso Pharmaceuticals is .

  • How much funding has Sorriso Pharmaceuticals raised over time?

    Sorriso Pharmaceuticals has raised $31M.

  • Who are Sorriso Pharmaceuticals’s investors?

    Biovision Ventures, Lundbeckfonden BioCapital, New Enterprise Associates, Pappas Capital, and Magnify have invested in Sorriso Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process